Skip to main content
SpringerLink
Log in

Medical Management of Advanced Disease

  • Chapter
  • First Online:
Management of Breast Cancer in Older Women

  • 490 Accesses

Abstract

Advanced or metastatic breast cancer is considered incurable, but not untreatable. The goals of treatment in older patients are not different from those in younger patients. For most patients with hormone receptor positive breast cancer, hormonal therapy should be the first choice. The use of chemotherapy should be considered in patients with hormone receptor-negative, hormone-refractory or life-threatening disease. Choice of chemotherapy regimens and agents is dependent on individual patient characteristics, preferences, and drug availability. Targeted treatments are used more and more, and also in older persons they can provide major clinical benefit with acceptable safety profile.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Thelen A, Benckert C, Jonas S, et al. Liver resection for metastases from breast cancer. J Surg Oncol. 2008;97:25–9.

    Article  PubMed  Google Scholar 

  2. Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 2015;16:1380–8.

    Article  PubMed  Google Scholar 

  3. Soran A, Ozmen V, Ozbas S, et al. A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01). Ann Surg Oncol. 2018;25(11):3141–9. https://doi.org/10.1245/s10434-018-6494-6. Epub 2018 May 17.

    Article  PubMed  Google Scholar 

  4. Wildiers H, Kunkler I, Biganzoli L, et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol. 2007;8:1101–15.

    Article  PubMed  Google Scholar 

  5. Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst. 2006;98:1285–91.

    Article  CAS  PubMed  Google Scholar 

  6. Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388:2997–3005.

    Article  CAS  PubMed  Google Scholar 

  7. de Groot AF, Kuijpers CJ, Kroep JR. CDK4/6 inhibition in early and metastatic breast cancer: a review. Cancer Treat Rev. 2017;60:130–8.

    Article  PubMed  Google Scholar 

  8. Singh H, Howie LJ, Bloomquist E, Wedam S, Amiri-Kordestani L, Tang S, Sridhara R, Ibrahim A, Goldberg K, McKee A, Beaver JA, Pazdur R. US Food and Drug Administration, Silver Spring, MD. A U.S. Food and Drug Administration pooled analysis of outcomes of older women with hormone-receptor positive metastatic breast cancer treated with a CDK4/6 inhibitor as initial endocrine based therapy. In San Antonio Breast Cancer Conference. San Antonio: 2017.

    Google Scholar 

  9. Kalsi T, Babic-Illman G, Fields P, et al. The impact of low-grade toxicity in older people with cancer undergoing chemotherapy. Br J Cancer. 2014;111:2224–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Sonke GS, Hart LL, Campone M, et al. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat. 2017;

    Google Scholar 

  11. Christman K, Muss HB, Case LD, Stanley V. Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience [see comment]. JAMA. 1992;268:57–62.

    Article  CAS  PubMed  Google Scholar 

  12. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29:3457–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118:3377–86.

    Article  PubMed  Google Scholar 

  14. Lin NU, Thomssen C, Cardoso F, et al. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast. 2013;22:203–10.

    Article  PubMed  Google Scholar 

  15. Hamberg P, Verweij J, Seynaeve C. Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy. Eur J Cancer. 2007;43:1514–28.

    Article  CAS  PubMed  Google Scholar 

  16. Wildiers H, Highley MS, de Bruijn EA, van Oosterom AT. Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet. 2003;42:1213–42.

    Article  CAS  PubMed  Google Scholar 

  17. Lichtman SM, Wildiers H, Chatelut E, et al. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients–an analysis of the medical literature. J Clin Oncol. 2007;25:1832–43.

    Article  CAS  PubMed  Google Scholar 

  18. Lichtman SM, Wildiers H, Launay-Vacher V, et al. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer. 2007;43:14–34.

    Article  PubMed  Google Scholar 

  19. Feher O, Vodvarka P, Jassem J, et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol. 2005;16:899–908.

    Article  CAS  PubMed  Google Scholar 

  20. Smorenburg CH, de Groot SM, van Leeuwen-Stok AE, et al. A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG. Ann Oncol. 2014;25:599–605.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Biganzoli L, Aapro M, Loibl S, et al. Taxanes in the treatment of breast cancer: have we better defined their role in older patients? A position paper from a SIOG Task Force. Cancer Treat Rev. 2016;43:19–26.

    Article  CAS  PubMed  Google Scholar 

  22. Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol. 2005;23:2155–61.

    Article  CAS  PubMed  Google Scholar 

  23. Colleoni M, Orlando L, Sanna G, et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol. 2006;17:232–8.

    Article  CAS  PubMed  Google Scholar 

  24. Albanell J, Ciruelos EM, Lluch A, et al. Trastuzumab in small tumours and in elderly women. Cancer Treat Rev. 2014;40:41–7.

    Article  CAS  PubMed  Google Scholar 

  25. Wildiers H, Tryfonidis K, Dal Lago L, et al. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Lancet Oncol. 2018;

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium

    Hans Wildiers

Authors
  1. Hans Wildiers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans Wildiers .

Editor information

Editors and Affiliations

  1. Brighton and Sussex Medical School, Brighton, UK

    Malcolm Reed

  2. Department of Surgery, Sahlgrenska University Hospital, Institute of Clinical Sciences, Gothenburg, Sweden

    Riccardo A. Audisio

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Wildiers, H. (2019). Medical Management of Advanced Disease. In: Reed, M., Audisio, R. (eds) Management of Breast Cancer in Older Women. Springer, Cham. https://doi.org/10.1007/978-3-030-11875-4_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-11875-4_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-11874-7

  • Online ISBN: 978-3-030-11875-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation